Morphine Market Trends

Global Morphine Market Overview

Morphine Market Size was valued at USD 16.2 Billion in 2023. The Morphine market industry is projected to grow from USD 17.27 Billion in 2024 to USD 26.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.50% during the forecast period (2024 - 2032). The rise in morphine use for pain management, the rise in orthopaedic disorders and chronic pain, and the rising number of cancer patients, are the key market drivers enhancing the market growth. 

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Morphine Market Trends

• The increase in prescription of painkillers for different illnesses is driving the market growth

The increase in the prescription of painkillers for a number of diseases, including cancer, cardiovascular issues, and arthritis, is predicted to hasten the market expansion between 2021 and 2028. It's also anticipated that the ageing population's health problems will fuel the growth of the morphine market. Additionally, market expansion is predicted to be fueled by the expanding patient population and the accelerating rate of market participant penetration. A further factor that is projected to affect the growth of the  morphine market is the increase in cancer cases and other diseases, such as cardiovascular problems. The market is expanding mostly due to the rising use of morphine as a painkiller. Morphine is one of the best methods for reducing pain. Additionally, most regions of the world permit its use in the management of severe and ongoing pain associated with complicated medical conditions. In addition, the increased incidence of orthopaedic disorders such osteoporosis, fibromyalgia, arthritis, and elbow pain is the main driver of the expansion of the morphine market value.

Morphine is one of the most effective drugs for pain management. Additionally, it is well acknowledged that using it to treat severe and persistent pain associated with significant medical illnesses is standard practises. Osteoporosis, fibromyalgia, elbow pain, and arthritis are a few of the orthopaedic conditions that are becoming more common, which is one of the main reasons why the market for morphine is growing so quickly. In accordance with an update from the World Health Organisation released in February 2021, 1.71 billion individuals ly experience musculoskeletal issues. The most widespread kind, low back ache, affects 568 million people worldwide. Since musculoskeletal problems are one of the leading causes of disability worldwide, the demand for its treatments is fueling the growth of the morphine market over the research period.

More than 32.5 million Americans have osteoarthritis in 2020, according to the Centres for Disease Control and Prevention. In the UK, the prevalence of osteoarthritis is constantly increasing. Furthermore, orthopaedic disorders are more prone to cause discomfort in elderly adults. As a result, the market will grow during the study period due to the predicted rise in the number of senior persons. As a result of the aforementioned variables, it is therefore projected that the studied market will be strongly driven during the study period. The growing number of people having surgeries has also had a favourable impact on the demand for opioids, especially for post-operative pain management, promoting quick recovery, and reducing patient issues. Additionally, the introduction of novel opioid varieties as a result of generic manufacturers' greater focus on the abuse-deterrent formulation (ADF) has increased demand for them as effective painkillers. Thus, driving the Morphine market revenue.

Morphine Market Segment Insights

Morphine Dosage Form Insights

The  Morphine market segmentation, based on dosage form, includes injection, oral, and other dosage forms. Injection segment dominated the  market in 2022. This is due to its enduring effects and prompt pain relief. Due to the increased prevalence of neurological diseases and the chronic pain they are associated with, there is also an increase in demand for the market's injection sector.

Figure 1:  Morphine Market, by Dosage Form, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Morphine Application Insights

The  Morphine market segmentation, based on application, includes pain management, diarrhea suppressant, cold & cough suppressant, and others. Pain management segment dominated the  Morphine market in 2022. Morphine, a painkiller, can be used to alleviate pain of any severity. Extended-release morphine pills and capsules are only used to treat extremely painful conditions that are uncontrollable with other medications. Furthermore, opioids are necessary for delivering adequate analgesia in severe post-operative situations.

Morphine Distribution Channel Insights

The  Morphine market segmentation, based on distribution channel, includes hospital pharmacies, retail pharmacies, online pharmacies, others. Online pharmacies segment dominated the  market in 2022. This is primarily because IoT adoption in the healthcare industry and rising internet penetration have led to the segment's high segmental growth over the course of the projected timeframe. 6.6% of the world's population, or 5.25 billion people, use the internet, and it is anticipated that this number will rise in the future.

Morphine End User Insights

The  Morphine market segmentation, based on end user, includes hospitals & clinics, ambulatory surgical centers, and others. Hospitals & clinics segment dominated the  Morphine market in 2022. This is a result of how easily accessible medicines are in clinics and hospitals. According to the CDC, 43.3 tablets per 100 individuals were prescribed morphine in the United States in 2020, which translates to 142.81 million prescriptions. It is predicted that high prescriptions will segment up as a result.

Morphine Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Morphine Market dominated this market in 2022 (45.80%). The existence of significant competitors, the prevalence of chronic diseases in the region, and the well-developed healthcare infrastructure are only a few of the critical factors influencing the market's expansion. Further, the U.S. Morphine market held the largest market share, and the Canada Morphine market was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil. 

Figure 2:  MORPHINE MARKET SHARE BY REGION 2023 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Morphine market accounted for the healthy market share in 2022. The market is expected to grow more quickly as a result of favourable government measures and an increase in research collaboration activity, among other things. Further, the German Morphine market held the largest market share, and the U.K Morphine market was the fastest growing market in the European region

The Asia Pacific Morphine market is expected to register significant growth from 2024 - 2032. The rising incidence of chronic diseases, especially cardiovascular conditions, is one of the primary factors driving market expansion. China is anticipated to experience the fastest increase due to its expanding population, greater patient pool, and simple access to cutting-edge therapies. Rising health spending in the area is also helping to fuel the growth of the Asia Pacific morphine market. Moreover, China’s Morphine market held the largest market share and the Indian Morphine market was the fastest growing market in the Asia-Pacific region.

Morphine Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Morphine market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Morphine industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the  Morphine industry to benefit clients and increase the market sector. In recent years, the Morphine industry has offered some of the most significant advantages to medicine. Major players in the Morphine market, including Mallinckrodt Pharmaceuticals, Alcaliber, Purdue Pharma, Sanofi Winthrop Industries, Macfarlan Smith, Sun Pharmaceutical Industries, Qinghai Pharmaceutical, Northeast Pharmaceutical Group, Pfizer Inc., Verve Health Care Ltd., Johnson Matthey Fine Chemicals, Manus Aktteva Biopharma LLP, Mayne Pharma Group Limited, Daiichi Sankyo Inc., and Taj Pharmaceuticals Limited, are attempting to increase market demand by investing in research and development Dosage Forms.

Amphastar Pharmaceuticals Inc. (Amphastar) is a specialised pharmaceutical company that develops, produces, and sells both generic and brand-name injectable, intranasal, and inhalation medications. It offers for sale pharmaceuticals with insulin as a primary component. Enoxaparin sodium injection, cosyntropin for injection, naloxone hydrochloride (HCl) injection, phytonadione injection, lidocaine jelly, amphadase hyaluronidase injection, epinephrine, naloxone, phytonadione, primatene mist, and glucagon are some of the company's best-selling products. Amphastar sells its goods to long-term care facilities, hospitals, clinics, and other locations that provide alternative healthcare. In the US, the UK, France, and China, the corporation sells its products through subsidiaries, specialty distributors, wholesalers, and retailers. The US city of Rancho Cucamonga is home to Amphastar's main office. The FDA authorised Amphastar Pharmaceuticals (US) to inject morphine sulphate in May 2021.

The pharmaceutical company Purdue Pharma LP (Purdue) produces pharmacologic drugs to treat and manage pain. The company creates, manufactures, and markets prescription and over-the-counter (OTC) pharmaceuticals in addition to other healthcare-related goods. Dietary supplements, laxatives, antiseptics, sedatives for sleep disorders, and prescription opioids are a few of its main product categories. Butrans, Hysingla, OxyContin, Senokot, Colace, Peri-Colace, Betadine, and SlowMag are just a few of the goods it offers for sale. The business also conducts clinical research on both novel and recently authorised medications. The business has locations in New Jersey and North Carolina. The US state of Connecticut, where Stamford is located, is home to the headquarters of Purdue. A patent was granted to Purdue Pharma (US) in September 2018 for an improved formulation of buprenorphine that reduces cravings and is used to treat opiate addiction, notably OxyContin addiction.

Key Companies in the Morphine market include

• Mallinckrodt Pharmaceuticals


• Alcaliber


• Purdue Pharma


• Sanofi Winthrop Industries


• Macfarlan Smith


• Sun Pharmaceutical Industries


• Qinghai Pharmaceutical


• Northeast Pharmaceutical Group


• Pfizer Inc.


• Verve Health Care Ltd.


• Johnson Matthey Fine Chemicals


• Manus Aktteva Biopharma LLP


• Mayne Pharma Group Limited


• Daiichi Sankyo Inc.


• Taj Pharmaceuticals Limited

Morphine Industry Developments

May 2022:Researchers from the University of Arizona Health Sciences and the Oklahoma State University Centre for Health Sciences have joined forces to confront the opioid issue and find and create state-of-the-art medicines for the management of chronic pain.

Morphine Market Segmentation

Morphine Dosage Form Outlook

• Injection


• Oral


• Other Dosage Forms

Morphine Application Outlook

• Pain Management


• Diarrhea Suppressant


• Cold & Cough Suppressant


• Others

Morphine Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies


• Others

Morphine End User Outlook

• Hospitals & Clinics


• Ambulatory Surgical Centers


• Others

Morphine Regional Outlook

• North America
  
  
  
  • US.
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America